Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on May 23, 2018, 10:39:25 am
-
Providing eight weeks of Gilead Sciences’ Epclusa (sofosbuvir/velpatasvir) through community pharmacies or prisons to individuals receiving opioid substitution therapy (OST) for addiction to opioids yields a high hepatitis C virus (HCV) cure rate, aidsmap reports.
Scottish researchers conducted an observational study of eight weeks of Epclusa treatment among 90 individuals receiving OST around Glasgow.
Read more...
https://www.hepmag.com/article/eight-weeks-gileads-epclusa-cures-high-rate-hep-c-opioid-addicts